Stocks · News reference

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Aug 10, 2026, 2:15 PMVandana Singh

Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 10, 2026, 2:15 PM
Checked: Aug 10, 2026, 2:15 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 12, 2026, 6:58 AMBenzinga Newsdesk
Reported Earlier, Silence Therapeutics Prices Upsized $175M Underwritten Public Offering Of 12,962,963 ADSs At $13.50 Per ADS
SLN
BenzingaAug 11, 2026, 3:52 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.
SLN
BenzingaAug 10, 2026, 8:04 PMBenzinga Newsdesk
Silence Therapeutics Announces Commencement Of Approximately $150M Underwritten Public Offering Of American Depositary Shares
SLN